Telswift

Telmisartan

Essential HTN in adults. Reduce risk of MI, stroke or death from CV causes in patients ≥55 yr at high risk of developing major CV events who are unable to take ACE inhibitors.

Essential HTN 40 mg once daily, may be increased to max: 80 mg once daily. Severe HTN Up to 160 mg alone or in combination w/ hydrochlorothiazide 12.5-25 mg dally. CV prevention 80 mg once daily. Mild to moderate hepatic impairment Not to exceed 40 mg once daily.

May be taken with or without food.

Hypersensitivity. Biliary obstructive disorders. Concomitant use w/ aliskiren-containing products in patients w/ DM or renal impairment (GFR <60 mL/min/1.73 m²). Severe hepatic impairment. 2nd & 3rd trimesters of pregnancy.

Not recommended in dual blockade of renin-angiotensin-aldosterone system, primary aldosteronism. Bilateral renal artery stenosis or artery stenosis to single functioning kidney; intravascular hypovolaemia; severe CHF; aortic or mitral stenosis, obstructive hypertrophic cardiomyopathy; hyperkalemia; ischaemic cardiomyopathy or CV disease. Patients w/ intercurrent events eg, dehydration, acute cardiac decompensation, metabolic acidosis, infectious diseases, cellular lysis. Diabetic patients treated w/ insulin or antidiabetics. Black patients. Monitor K & serum creatinine levels periodically in patients w/ renal impairment. Not to be co-administered w/ aliskiren in diabetic patients. Not to be used concomitantly w/ ACE inhibitors in patients w/ diabetic nephropathy. Avoid use w/ aliskiren in patients w/ renal impairment (GFR <60 mL/min). Not recommended to be used w/ ACE inhibitor. Concomitant use w/ K-sparing diuretics, K supplements, K-containing salt substitutes, NSAIDs including COX-2 inhibitors, immunosuppressives, trimethoprim, other drugs increasing K level eg, heparin. Not to be given in patients w/ cholestasis, biliary obstructive disorders or severe hepatic impairment. Recent kidney transplantation; underlying renal disease, renal artery stenosis. Mild to moderate hepatic impairment. Not recommended during 1st trimester of pregnancy & lactation. Childn <18 yr. Elderly >70 yr.

Hypotension.

Increased digoxin peak plasma & trough conc. Increased serum K w/ K-containing salt substitutes, K-sparing diuretics, K supplements, ACE inhibitors, heparin, immunosuppressives (cyclosporin, tacrolimus), trimethoprim. Reversible increased serum lithium conc & toxicity. Reduced antihypertensive effects w/ NSAIDs including COX-2 inhibitors; systemic corticosteroids. Vol depletion & increased risk of hypotension w/ high-dose diuretics. Not recommended in concomitant use w/ ramipril. Increased BP-lowering effect w/ other antihypertensives. Potentiated hypotensive effects w/ baclofen, amifostine. Aggravated orthostatic hypotension w/ alcohol, barbiturates, narcotics, antidepressants.

Angiotensin II Antagonists

C09CA07 - telmisartan ; Belongs to the class of angiotensin II receptor blockers (ARBs). Used in the treatment of cardiovascular disease.

B